Aldeyra Therapeutics, Inc. (ALDX) hit his 1-Year Low price on 05/09/17

Marco Green
September 14, 2017

We have $6.96 PT which if reached, will make NASDAQ:ALDX worth $6.89M more.

ALDX has been the subject of several other research reports. Zacks Investment Research lowered shares of Aldeyra Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 30th.

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) is a huge mover today! Cowen & Co maintained the stock with "Buy" rating in Wednesday, August 9 report. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock.

The consensus recommendation - averaging the work of 1 analysts - of 2 for Second Sight Medical Products, Inc. 13,700 shares valued at $1.59M were sold by MIZELL STEVEN on Monday, April 10. With the move the stock is now valued at $6.20.As we move deeper into earnings season, investors may be trying to figure out how to best position the portfolio for the rest of the calendar year.

In taking a look at technical levels, shares are trading -2.05% away from the 50 day simple moving average and -29.65% away from the 200 day simple moving average. The company holds 15.33 million outstanding shares and 14.88 million shares are floating in market.

Aldeyra Therapeutics (NASDAQ ALDX) opened at 5.65 on Wednesday. However a year ago for the same quarter the company has reported $-0.38 EPS. The other 5, though not evenly; between analysts who think you should buy Aldeyra Therapeutics, Inc. versus those who think you should sell it.

WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & global trademark & copyright law. Awm Invest has invested 0.96% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). The stock was acquired at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Finding stocks that look good on paper but have fallen out of favor with certain investors may be a good place to start doing some further number crunching.

Institutions own 49.09% of Aldeyra Therapeutics, Inc. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company's stock valued at $1,431,000 after buying an additional 9,407 shares in the last quarter. Finally, Hikari Power Ltd grew its stake in Aldeyra Therapeutics by 186.4% during the 2nd quarter. Perceptive Ltd Liability Corp reported 0.74% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). They expect $-0.38 earnings per share, down 642.86% or $0.45 from last year's $0.07 per share.

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The New York-based Tower Cap Ltd Limited Liability Company (Trc) has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). The Company's principal activities include raising capital and research and development activities. This approach reduces aldehyde levels, introducing a new treatment option that could help millions of people alleviate their dry eye disease symptoms worldwide.

Other reports by Click Lancashire

Discuss This Article